Jazz Pharma's decision to revoke U.S. patent for rival narcolepsy drug

Published Date: 02 Mar 2023

A U.S. court on Friday ordered Jazz Pharmaceuticals to revoke its patents related to its flagship narcolepsy drug Xyrem from the FDA-approved brand name drug after winning a case against Avadel foe CNS Pharmaceuticals.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Zebrafish models offer fast, effective guidance for personalized therapies for kids with high-risk cancer

2.

GLP-1 drugs linked to dramatically lower death rates in colon cancer patients

3.

Glofitamab Regimen Improves Survival in DLBCL

4.

Artificial intelligence is assisting in the earlier detection and treatment of breast cancer.

5.

Treating advanced prostate cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot